Financial Survey: Check-Cap (CHEK) and Its Rivals

Check-Cap (NASDAQ: CHEK) is one of 19 publicly-traded companies in the “Specialty & Advanced Pharmaceuticals” industry, but how does it weigh in compared to its peers? We will compare Check-Cap to similar companies based on the strength of its profitability, earnings, dividends, institutional ownership, analyst recommendations, risk and valuation.


This table compares Check-Cap and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Check-Cap N/A -98.88% -80.97%
Check-Cap Competitors -538.85% -41.85% -24.81%

Analyst Ratings

This is a summary of recent recommendations and price targets for Check-Cap and its peers, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Check-Cap 0 0 3 0 3.00
Check-Cap Competitors 98 367 965 28 2.63

Check-Cap presently has a consensus target price of $6.00, indicating a potential upside of 238.98%. As a group, “Specialty & Advanced Pharmaceuticals” companies have a potential upside of 26.75%. Given Check-Cap’s stronger consensus rating and higher possible upside, analysts clearly believe Check-Cap is more favorable than its peers.

Institutional & Insider Ownership

19.3% of Check-Cap shares are owned by institutional investors. Comparatively, 66.5% of shares of all “Specialty & Advanced Pharmaceuticals” companies are owned by institutional investors. 10.0% of shares of all “Specialty & Advanced Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Check-Cap and its peers top-line revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Check-Cap N/A -$9.62 million -3.00
Check-Cap Competitors $2.40 billion $905.93 million 3.52

Check-Cap’s peers have higher revenue and earnings than Check-Cap. Check-Cap is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Volatility & Risk

Check-Cap has a beta of -0.37, meaning that its stock price is 137% less volatile than the S&P 500. Comparatively, Check-Cap’s peers have a beta of 0.81, meaning that their average stock price is 19% less volatile than the S&P 500.


Check-Cap peers beat Check-Cap on 8 of the 12 factors compared.

Check-Cap Company Profile

Check-Cap Ltd. (Check-Cap) is a clinical-stage medical diagnostics company. The Company is engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The Company’s system consists of main components, such as ingestible scanning capsule; Capsule Positioning System (CPS), a recorder worn on the patient’s back, and a personal computer (PC)-based work station for data reconstruction and image processing. The Company’s scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. Its scanning capsule employs low-dose X-rays, which allow the system to image the interior lining of the colon even when surrounded by intestinal content. Its capsule transmits information to a receiving device worn on the patient’s body that stores the information for off-line analysis.

Receive News & Ratings for Check-Cap Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check-Cap Ltd. and related companies with's FREE daily email newsletter.

Leave a Reply